Mark Surka is currently the Head of Medical Affairs for Oncology, Rare, and Rare Blood Diseases at Sanofi, a position held since 2024, and was previously the Head of Medical Affairs for Oncology at Sanofi Genzyme from 2018 to 2024. They have a robust background in oncology and nephrology, having served as a Sr. Scientific Lead at Janssen, as well as holding roles such as Medical Science Liaison and Scientific Advisor at Bristol-Myers Squibb. Mark holds a Ph.D. in Biochemistry from the University of Toronto and a BSc in Biochemistry and Chemistry from Western University. Prior experiences include positions at The Hospital for Sick Children and The Scripps Research Institute.
This person is not in the org chart
This person is not in any teams
This person is not in any offices